Although anti-CTLA-4 therapy was initially used to augment the activity of tumor-infiltrating CD8+ T and CD4+ T cells, it has been suggested that this therapy exerts its effects through a cTreg-depleting effect in the tumor site (34). This evidence concerns the gene CD8A and neoplasm.